You can buy or sell IMV and other stocks, options, ETFs, and crypto commission-free!
IMV, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm's patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Read More The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.
Dartmouth, Nova Scotia
52 Week High
52 Week Low
Financial PostMay 10
IMV Announces Annual and Special Meeting of Shareholders Voting Results
DARTMOUTH, Nova Scotia — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company (or the ”Corporation”), today announced the voting results from its Annual and Special Meeting of Shareholders held on Thursday May 9, 2019. Based on the proxies received and the votes on a show of hands, all resolutions were accepted including the election of Directors for whom details of the votes are as follows; Name of Nominee Votes cast FOR % of votes cast FOR Julia Gregory 26,089,068 99.90% James H. Ha...
Yahoo FinanceMay 9
IMV Inc. Announces Q1 2019 Financial Results and Clinical Program Advances
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, today released its financial and operational results for the first quarter ended March 31, 2019. “The DPX-Survivac program continues to be a major value-driver for IMV, with its unique mechanism of action providing significant clinical differentiation and, potentially, a much-needed innovation for hard-to-treat cancers,” said Frederic Ors, IMV's Chief Executive Officer. “Highlights of our ov...
Markets InsiderMay 8